Research on cancer therapy reported by scientists at University of Paris
2007 NOV 19 -- Data detailed in 'Sterically stabilized superparamagnetic liposomes for MR imaging and cancer therapy: pharmacokinetics and biodistribution' have been presented. According to a study from France, "Pharmacokinetics of magnetic-fluid-loaded liposomes (MFLs) with mean hydrodynamic diameter of 200 nm sterically stabilized by poly(ethylene glycol) (PEG) and labelled by a fluorescent lipid probe, N-(lissamine rhodamine B sulfonyl) phosphatidylethanolamine (Rho-PE) was studied. The loading consisted in an aqueous suspension of maghemite nanocrystals close to 8 nm in size at 1.7 Fe(III)mol/mol total lipids ratio." "Double tracking of MFL in blood was performed versus time after intravenous administration in mice. Lipids constituting vesicle membrane were followed by Rho-PE fluorescence spectroscopy while iron oxide was determined independently by relaxometry. MFLs circulating in the vascular compartment conserved their vesicle structure and content. The pharmacokinetic profile was characterized by two first-order kinetics of elimination with distinct plasmatic half-lives of 70 min and 12.5 h. Iron biodistribution and organ histology clearly highlighted preferential MFL accumulation within liver and spleen. The pathway in spleen supported that elimination was governed by the mononuclear phagocyte system (MPS). PEG coating was essential to prolong MFL circulation time whereas iron oxide loading tends to favour uptake by the MPS," wrote V. Plassat and colleagues, University of Paris. The researchers concluded: "Despite partial uptake in the earlier times after administration, MFLs exhibited long circulation behaviour over a 24-h period that, coupled to magnetic targeting, encourages further use in drug delivery." Plassat and colleagues published the results of their research in International Journal of Pharmaceutics (Sterically stabilized superparamagnetic liposomes for MR imaging and cancer therapy: pharmacokinetics and biodistribution. International Journal of Pharmaceutics, 2007;344(1-2):118-27). For additional information, contact V. Plassat, Universite Paris-Sud, Laboratoire Physico-Chimie Pharmacotechnie Biopharmacie, UMR CNRS 8612, Faculte de Pharmacie, 5 rue Jean-Baptiste Clement, F-92296 Chatenay-Malabry Cedex, France. The publisher of the International Journal of Pharmaceutics can be contacted at: Elsevier Science BV, PO Box 211, 1000 AE Amsterdam, Netherlands. Keywords: France, Cancer Therapy, Cancer, Drugs, Nanotechnology, Oncology, Pharmaceuticals, Pharmacokinetics, Therapies, Therapy, Treatment. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
